nct_id: NCT06311721
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2024-03-15'
study_start_date: '2024-09-09'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: ABP 234'
  - drug_name: 'Drug: Pembrolizumab (US)'
  - drug_name: 'Drug: Pembrolizumab (EU)'
long_title: "A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics,\
  \ Safety, and Immunogenicity Between ABP 234 and Keytruda\xAE (Pembrolizumab) in\
  \ Subjects With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer"
last_updated: '2025-11-13'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE3
principal_investigator: NA
principal_investigator_institution: Amgen
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 927
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- 1. At least 18 years of age.
- 2. Histologically or cytologically confirmed stage IV non-squamous Non-Small Cell
  Lung Cancer (NSCLC).
- 3. Participant has no prior systemic treatment for advanced disease.
- 4. Measurable disease according to RECIST v1.1.
- 5. Tumor tissue from the resected site of disease must be available for biomarker
  analyses in order to be randomized.
- 6. Eastern Cooperative Oncology Group performance status score 0 or 1.
- 7. Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and
  c-ros oncogene 1, receptor tyrosine kinase of the insulin receptor family (ROS-1)
  negative
- 8. Have a life expectancy of at least 3 months.
- 'Exclude - Exclusion Criteria:'
- Exclude - 1. Small cell lung cancer (SCLC) or mixed SCLC/NSCLC histology or squamous
  cell carcinoma.
- Exclude - 2. Participant has active central nervous system metastases not previously
  treated.
- Exclude - 3. Participant has active or known immune-mediated disorders.
- Exclude - 4. Participant has received prior systemic cytotoxic chemotherapy, immunotherapy
  (including PD-1/PD-L1), anti-neoplastic biological therapy, or targeted therapy
  for advanced/metastatic disease.
- Exclude - 5. Known hypersensitivity to monoclonal antibodies or to any of the excipients
  of the study drug, or to any component of cisplatin, carboplatin, or pemetrexed.
short_title: "A Study to Compare ABP 234 and Keytruda\xAE (Pembrolizumab) in Participants\
  \ With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer"
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Amgen
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: "The primary objective of this study is to compare the efficacy of ABP 234\
  \ with the pembrolizumab reference product (Keytruda\xAE)."
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: ABP 234
      arm_internal_id: 0
      arm_description: 'Part 1: Participants will receive ABP 234 followed by pemetrexed
        administered with platinum-based chemotherapy (cisplatin or carboplatin).
        Part 2: Participants will receive ABP 234 followed by pemetrexed.'
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: ABP 234'
        level_internal_id: 0
        level_suspended: N
    - arm_code: Pembrolizumab (US)
      arm_internal_id: 1
      arm_description: 'Part 1: Participants will receive FDA-licensed pembrolizumab
        followed by pemetrexed administered with platinum-based chemotherapy (cisplatin
        or carboplatin). Part 2: Participants will receive FDA-licensed pembrolizumab
        followed by pemetrexed.'
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Pembrolizumab (US)'
        level_internal_id: 0
        level_suspended: N
    - arm_code: Pembrolizumab (EU)
      arm_internal_id: 2
      arm_description: 'Part 1: Participants will receive EU-approved pembrolizumab
        followed by pemetrexed administered with platinum-based chemotherapy (cisplatin
        or carboplatin). Part 2: Participants will receive EU-approved pembrolizumab
        followed by pemetrexed.'
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Pembrolizumab (EU)'
        level_internal_id: 0
        level_suspended: N
    match:
    - clinical:
        age_numerical: '>=18'
        disease_status:
        - Metastatic
        - Untreated
        oncotree_primary_diagnosis: Non-Small Cell Lung Cancer
